Treatment of complement-associated disorders
US7419663B2 · kind B2 · utility
24Cited by
2References
24Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Oct 12, 2004 |
| Grant date | Sep 2, 2008 |
| Priority date | — |
| Expiry date | Apr 25, 2025 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY10S424/81
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention concerns a recently discovered macrophage specific receptor, STIgMA, and its use in the treatment of complement-associated disorders.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.